Bod Australia (ASX:BOD) - CEO, Jo Patterson
CEO, Jo Patterson
Source: Jo Patterson/LinkedIn
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Bod Australia (BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to the Australian market in July
  • The product will be sold as Bod Bio-Absorb 100 and is made up of a uniquely developed CBD formulation in a soft gel format
  • The launch of Bio-Absorb 100 will expand Bod’s medicinal cannabis range, complement its existing products and introduce a new delivery format
  • To drive product awareness, Bod has engaged multiple healthcare professionals and prescribers to further educate them on the benefits of Bio-Absorb 100
  • Bod ends the day 12.7 per cent in the green with shares trading at eight cents

Bod Australia (BDA) will launch a new medicinal cannabis product under its existing MediCabilis brand to the Australian market in July.

The product will be sold as Bod Bio-Absorb 100 and is made up of a uniquely developed CBD formulation in a soft gel format.

It is currently undergoing a phase II clinical trial and, once completed, it will be sold over-the-counter through pharmacies.

The launch of Bio-Absorb 100 will expand Bod’s medicinal cannabis range, complement its existing products and introduce a new delivery format.

To drive product awareness, Bod has engaged multiple healthcare professionals and prescribers to further educate them on the benefits of Bio-Absorb 100.

Further, it is available to consumers through the Therapeutic Goods Administration’s (TGA) Special Access Scheme Category B (SAS-B).

The TGA’s SAS allows healthcare practitioners to access therapeutic goods such as medicines, medical devices and biologicals that are not included in the Australian Register of Therapeutic Goods.

“The launch of Bod Bio-Absorb 100 provides Bod with another product in the Australian
medicinal cannabis prescription market, which has the potential to increase sales and brand awareness,” CEO Jo Patterson said.

“Importantly, the introduction of the product through prescription channels will also provide us with valuable feedback as we continue our clinical trial and endeavour to launch Bod Bio-Absorb 100 through the Australian pharmacy market in the coming months.”

Bod has ended the day 12.7 per cent in the green with shares trading at 8 cents.

BOD by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…